BioSpace News Archive

Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock.

Company Continues to Drive Down Expenses as it Expects to Achieve Adjusted EBITDA break-even in the 2019 Fourth Quarter

Exceeded 125 REMS-certified facilities two months ahead of year-end goal

Invitae Corporation, a leading medical genetics company, announced financial and operating results for the third quarter ended September 30, 2019.

Natera, Inc., a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, reported financial results for the third quarter ended September 30, 2019 and provided an update on recent business progress.

DiaMedica Therapeutics Inc. announced that its third quarter 2019 financial results will be released after the markets close on Wednesday, November 13th.

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, reported financial results for the third quarter ended September 30, 2019 and provided a general business update.

Presented by St. Michael’s Hospital Foundation, the fifth annual Angels Den will showcase the projects of eight finalists as they compete for funding to bring their ideas to life.

LimFlow SA announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the LimFlow Percutaneous Deep Vein Arterialization System.

David L. Bartlett, MD, a pioneer in abdominal cancer treatment, also serves as president of the Society of Surgical Oncology [06-November-2019] PITTSBURGH , Nov. 6, 2019 /PRNewswire/ -- David L. Bartlett , MD, an internationally recognized cancer researcher and a pioneer in the use of highly advanced surgical therapies for abdominal cancers, has been appointed Chair